Adding marquee investors, BlackThorn bags $76M to back an AI-driven strategy for precision neuro medicine
As artificial intelligence and machine learning loom ever larger in drug discovery and development, a biotech operating at the “nexus” of technology and neurosciences has cashed in with $76 million in fresh financing.
The big idea at BlackThorn Therapeutics is to do for neurobehavioral disorders what genetically targeted therapy has done for oncology: Redefine patient populations by the underlying biology — dysregulated brain circuits, or neurotypes — instead of symptoms, thereby finding the patients who are most likely to benefit at enrollment phase.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.